Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 934,300 shares, a decrease of 23.4% from the January 31st total of 1,220,000 shares. Based on an average daily trading volume, of 690,700 shares, the days-to-cover ratio is currently 1.4 days. Currently, 1.3% of the shares of the stock are short sold.

Tiziana Life Sciences Trading Down 12.4 %

Shares of NASDAQ:TLSA opened at $1.13 on Tuesday. The business’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $0.90. Tiziana Life Sciences has a one year low of $0.41 and a one year high of $1.74.

Institutional Trading of Tiziana Life Sciences

Large investors have recently made changes to their positions in the stock. Bison Wealth LLC acquired a new position in Tiziana Life Sciences in the 4th quarter valued at about $30,000. Zhang Financial LLC grew its holdings in shares of Tiziana Life Sciences by 34.3% during the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock worth $65,000 after buying an additional 23,800 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Tiziana Life Sciences by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after buying an additional 27,041 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of Tiziana Life Sciences in the third quarter valued at approximately $864,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.